Sinovac's president said Chinese officials approved using the company's Covid-19 vaccine for children 3-17 years old.

Sinovac has conducted clinical research on the minor group since the beginning of this year, the first phase clinical trial and the second phase has been completed, Doan Defense, Sinovac company president, today said.

Mr. Doan said that when the company's Covid-19 vaccine was injected for children 3-17 years, it depends on the government's vaccination strategy.

China has been injected with 723.5 million doses of Vaccine Covid-19 to June 3 and currently only vaccinated for people aged 18 and over.

Doan Guard, Chairman of Sinovac Company, in a conference in Uncle Ngao, Hai Nam province, in April. Photo: Xinhua.

The results of clinical trials Phase I and II preliminary shows that the Sinovac vaccine can activate the immune response in the tester aged 3-17, the side effect is light.

Sinopharm, China State-State Pharmaceutical Company, Sinovac similar technology vaccine production unit, is also applying for licensing for younger groups.

Sinovac has completed phase II clinical trials, where participants are injected a third consumption dose, after completing the two common injections, Mr. Doan said.

However, President Sinovac warned still further observation than the antibody time existed before recommending the third inginning time for the authorities.